Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2025-12-08 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
关于控股子公司两款药品新纳入国家医保目录的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Changchun High & New Technology Industries (Group) Co., Ltd. regarding the inclusion of two drugs from its controlling subsidiary into the national medical insurance catalog for 2025. It provides detailed information about the drugs, their clinical indications, and the impact on the company. The document is a formal public announcement about a regulatory or business development event, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. It is not a report publication announcement since it contains substantive content rather than just a notice of report availability. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement about product inclusion in a government insurance catalog, which is material information for investors but does not fit other specific categories.
2025-12-08 Chinese
关于子公司GenSci142胶囊境内生产药品注册临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a clinical trial application for a pharmaceutical product by a subsidiary. It includes details about the drug, regulatory approval from the National Medical Products Administration, and the impact and risks related to the clinical trial. The document is relatively short (1486 characters) and serves as a formal announcement of regulatory approval rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed investor presentation content. It is not an annual or interim report, earnings release, or any form of shareholder meeting material. The content fits best under a general regulatory announcement category, as it informs investors and the public about a significant regulatory milestone affecting the company but does not constitute a financial or governance report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-11-27 Chinese
关于控股股东股权结构发生变更的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding a change in the equity structure of the company's controlling shareholder. It details the transfer of shares between entities but explicitly states that the controlling shareholder and actual controller remain unchanged. There is no financial data, no report attached or referenced, and no mention of a meeting or voting results. This fits the category of a Major Shareholding Notification, as it informs about changes in significant share ownership levels (even though the ultimate control remains the same). The document length is short and focused solely on ownership structure changes, which aligns with MRQ rather than other categories like MANG or SHA.
2025-11-20 Chinese
关于子公司注射用GenSci140境内生产药品注册临床试验申请获批的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Changchun High & New Technology Industry Group Co., Ltd. regarding the approval of a clinical trial application for a drug developed by its subsidiary. It details the drug's characteristics, the approval by the National Medical Products Administration, and the potential impact and risks. The document is a regulatory announcement about a clinical trial approval, not a financial report, earnings release, or management discussion. It does not contain financial data or detailed financial analysis. It is a formal announcement of a regulatory approval event relevant to investors. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-11-14 Chinese
关于回购公司股份期限届满暨回购完成的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Changchun High-tech Industry (Group) Co., Ltd. regarding the completion of its share repurchase program. It details the repurchase period expiration, the number of shares repurchased, prices, compliance with regulations, and the intended use of the repurchased shares for employee incentive plans. The document does not contain financial statements or quarterly/yearly financial results but focuses on the share buyback activity and its compliance. This matches the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares. The document length is 2731 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is POS with high confidence.
2025-11-14 Chinese
关于子公司GS3-007a干混悬剂境内生产药品临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a clinical trial application for a pharmaceutical product by a subsidiary. It contains no financial statements, no management discussion of financial results, no earnings data, and no regulatory certifications or officer attestations. The document is relatively short (1157 characters) and focuses on a specific operational update related to drug development and regulatory approval. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The content is a regulatory announcement about a clinical trial approval, which is best classified under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2025-11-14 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.